![Mervyn Rees Thomas](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mervyn Rees Thomas
No más puestos en curso
Historial de carrera de Mervyn Rees Thomas
Antiguos cargos conocidos de Mervyn Rees Thomas.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Immunexpress, Inc.
![]() Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Fundador | 01/01/2010 | - |
Immunexpress Pty Ltd.
![]() Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Fundador | 01/01/2006 | - |
Consejero General | 01/01/2006 | - |
Estadísticas
Internacional
Australia | 2 |
Estados Unidos | 2 |
Operativa
Founder | 2 |
General Counsel | 1 |
Sectorial
Health Technology | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Immunexpress Pty Ltd.
![]() Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Health Technology |
Immunexpress, Inc.
![]() Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Commercial Services |
- Bolsa de valores
- Insiders
- Mervyn Rees Thomas
- Experiencia